drugset
drugset / Trial / NCT02942160

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02942160 ↗

Phase 2 Completed 259 enrolled Endo USA Inc., a Keenova Therapeutics Company
NaSingle-groupOpen-labelTreatment

Summary

A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).

Timeline

Start
2016-10-05
Primary completion
2018-06-14
Completion
2018-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.84 mg —

Indications

cellulitis panniculitis and localized lipodystrophy